Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

HLA-DRA antibody

HLA-DRA Reactivity: Human FACS, IF Host: Mouse Monoclonal IPO-10 unconjugated
Catalog No. ABIN6937412
  • Target See all HLA-DRA Antibodies
    HLA-DRA (HLA Class II DR alpha (HLA-DRA))
    Reactivity
    • 83
    • 17
    • 10
    • 10
    • 9
    • 9
    • 3
    • 2
    • 2
    • 1
    Human
    Host
    • 56
    • 42
    • 1
    • 1
    Mouse
    Clonality
    • 57
    • 43
    Monoclonal
    Conjugate
    • 48
    • 12
    • 5
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    This HLA-DRA antibody is un-conjugated
    Application
    • 44
    • 43
    • 33
    • 31
    • 16
    • 11
    • 10
    • 9
    • 9
    • 3
    • 3
    • 3
    • 1
    • 1
    • 1
    Flow Cytometry (FACS), Immunofluorescence (IF)
    Specificity
    MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected. '
    Cross-Reactivity (Details)
    Human. Monkey.
    Purification
    1.0mg/ml of Ab purified from Bioreactor by Protein A/G.
    Immunogen
    Spleen cells of a patient with hairy cell leukemia (Daudi cells)
    Clone
    IPO-10
    Isotype
    IgG3 kappa
    Top Product
    Discover our top product HLA-DRA Primary Antibody
  • Application Notes

    Known_Application: Flow Cytometry (1-2 μg/million cells), Immunofluorescence (1-2 μg/mL), Optimal dilution for a specific application should be determined.

    Positive_Control: Ramos, Daudi or HuT78 cells. Tonsil or lymph node.

    Restrictions
    For Research Use only
  • Concentration
    1.0 mg/mL
    Buffer
    Prepared in 10 mM PBS, WITHOUT BSA and Azide.
    Preservative
    Azide free
    Storage
    -20 °C,-80 °C
    Storage Comment
    Antibody without azide store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous.
    Expiry Date
    24 months
  • Target
    HLA-DRA (HLA Class II DR alpha (HLA-DRA))
    Alternative Name
    HLA-DRA (HLA-DRA Products)
    Synonyms
    HLA-DRA1 antibody, MLRW antibody, DR-alpha antibody, HLA-DRA antibody, Mamu-DRA1 antibody, major histocompatibility complex, class II, DR alpha L homeolog antibody, major histocompatibility complex, class II, DR alpha antibody, hla-dra.L antibody, HLA-DRA antibody, MAMU-DRA antibody, BOLA-DRA antibody
    Background
    DR alpha chain, HLA class II histocompatibility antigen, HLA class II histocompatibility antigen DR alpha chain, HLA DRA, HLA DRA1, HLA-DRA, HLADRA1, Major histocompatibility complex class II DR alpha, MHC cell surface glycoprotein, MHC class II antigen DRA,HLA-DRA (MHC II)
    Cellular localisation: Cell surface
    Molecular Weight
    ~36kDa
    Gene ID
    3122, 520048
    UniProt
    P01903
    Pathways
    TCR Signaling, CXCR4-mediated Signaling Events
You are here:
Support